Tolvaptan is the only drug approved to slow cyst growth and preserve kidney function in patients with autosomal dominant polycystic kidney disease (ADPKD). However, its limited efficacy combined with significant side effects underscores the need to identify new and safe therapeutic drug targets to slow progression to end stage kidney disease. We identified DDR1 as receptor tyrosine kinase upregulated in vivo in 3 mouse models of ADPKD using a novel mass spectrometry approach to identify kinases upregulated in ADPKD. Previous studies demonstrating critical roles for DDR1 to cancer progression, its potential role in the pathogenesis of a variety of other kidney disease, along with the possibility that DDR1 could provide new insight into how extracellular matrix impacts cyst growth led us to study the role of DDR1 in ADPKD pathogenesis. However, genetic deletion of DDR1 using CRISPR/Cas9 failed to slow cyst growth or preserve kidney function in both a rapid and slow mouse model of ADPKD demonstrating that DDR1 does not play a role in PKD pathogenesis and is thus a not viable drug target. In spite of the negative results, our studies will be of interest to the nephrology community as it will prevent others from potentially conducting similar experiments on DDR1 and reinforces the potential of performing unbiased screens coupled with in vivo gene editing using CRISPR/Cas9 to rapidly identify and confirm new potential drug targets for ADPKD.
Introduction
Dysregulation of kinases and the pathways they regulate play a prominent role in the pathogenesis of cyst growth in ADPKD 1, 2 . Moreover, pharmacologic inhibition of a number of different kinases up-regulated in ADPKD kidneys has been shown to slow cyst growth in animal models making kinase inhibitors among the most promising class of drugs for treating patients with ADPKD. We identified Discoidan Domain Receptor 1 (DDR1) as a previously unidentified kinase to be upregulated in 3 mouse models of ADPKD using a novel mass spectrometry approach [3] [4] [5] . DDR1 is a receptor tyrosine kinase (RTK) that mediates interaction with the extracellular matrix and is activated upon binding collagen 6, 7 . Recent evidence has indicated that DDR1 is up-regulated in various cancers and plays a role in tumor growth, progression, and invasion [8] [9] [10] [11] . DDR1 has also been shown to play prominent roles in a number of kidney disease that include mouse models of Alports 12, 13 , obstructive uropathy 14 , the remnant kidney model of chronic kidney disease 15 and nephrotoxic serum nephritis 16 (see the excellent review 17 ). Thus, based on these findings we entertained the possibility that DDR1 would play a prominent role in PKD pathogenesis and provide a link between the extracellular matrix and regulation of growth of cyst lining epithelia. However, despite the upregulation of both DDR1 protein and DDR1 kinase activity in vivo in mouse models of ADPKD, targeted deletion of DDR1 using CRISPR/Cas9 did not slow cyst growth or preserve kidney function in both an ""early rapid" and "late slow" mouse model of ADPKD. containing a cocktail of phosphatase inhibitors as previously described 4, 5 . Bound kinases were then identified by LC separation followed by tandem mass spectrometry (LC-MS/MS) 4, 5 .
Materials and Methods

Mass
Experiments were performed using 6 PKD and 6 WT kidneys isolated from independent animals (3 female and 3 male mice in each group).
Genetic Deletion of DDR1 using CRISPR/Cas9. 6 single-guide (sg) RNAs using Feng Zhang's on line tool were screened in ES cells for their ability to create double strand breaks (DSB) in DDR1 and ultimately led to the identification of 2 sgRNAs complementary to regions in exons 2 and 3 of DDR1 that were most efficient in giving DSB and corresponded to with the following sequences: AGTAACGCAACCGATAGCTT and CTACCGCTGCCCGCCACAGC (see schematic Fig.   3a ). RNA for these 2 sgRNAs were in vitro transcribed, purified, and microinjected together with and kidneys were harvested 14 weeks post induction as previously described 20 . All animals were used in accordance with scientific, humane, and ethical principles and in compliance with regulations approved by the New York University School of Medicine Institutional Animal Care and Use Committee.
Cystic index and kidney immunohistochemistry. Kidneys were harvested, fixed in 4% paraformaldehyde for 4 hours at 4 0 C, and sagittal kidney sections were stained with hematoxylin and eosin. Sections were then photographed under the same magnification and cystic index was calculated using ImageJ analysis software on 2 sagittal sections/kidney as described 21, 22 . Cystic index was calculated as the cumulative cyst volume per total area of kidney 21, 22 .
Kidney immunohistochemistry was performed on ADPKD and normal human kidneys Chromogenic immunohistochemistry was performed on a Ventana Medical Systems Discovery XT platform with online deparaffinization, antigen retrieval and using Ventana's reagents and detection kits. In brief, heat mediated antigen retrieval was performed using either CC1 (TrisBorate-EDTA, pH 8.5) or RCC2 (Sodium Citrate pH6.0) as required. Endogenous peroxidase activity was blocked with 3% hydrogen peroxide. Primary antibodies were diluted in Dulbecco's phosphate buffered saline (Life Technologies) 3 hours at 37°C and detected using anti-rabbit or anti-mouse HRP labeled multimers incubated for 8 minutes. The complex was visualized with 3,3 diaminobenzidene and enhanced with copper sulfate.
Western Analysis: Kidneys harvested at time of sacrifice were flash frozen in liquid nitrogen, homogenized in lysis buffer, separated by SDS/PAGE, immunoblotted with primary antibody as indicated, and detected with a Li-cor IRdye secondary antibody as described 21 . quantitative LC-MS (MIB) as previously described 4, 5 . One of the kinases identified was DDR1.
Antibodies
We found that DDR1 protein and activity (assessed by anti-phospho-DDR1 antibodies) was increased in kidneys from 3 mouse models of ADPKD that included 2 "early, rapid" models in (Fig. 1a) . In addition, DDR1 is expressed in mouse and human cyst lining epithelia (Fig. 1b) . (Fig. 2a-e) . To assess the signaling pathways affected by dasatinib treatment, kidneys from control and dasatinib treated mice were probed with various anti-phospho-antibodies. These studies demonstrated that dasatinib treatment not only inhibited activation of DDR1, but also Stat3 and AKT, while MAPK was not inhibited (Fig. 2f) .
Inhibiting
Although these experiments provided a proof of concept that inhibiting DDR1 may slow cyst growth, dasatinib also inhibits other kinases [23] [24] [25] , such as Src family kinases and Kit. (Fig. 3a) .
Genetic deletion of DDR1 fails to slow cyst growth and preserve renal function in
DDR1 and phospho-DDR1 (pDDR1) were absent from kidneys from DDR1 -/-; Pkhd1-Cre; Pkd1 fl/fl mice confirming that our antibodies are specific for DDR1 and that we generated DRR1 -/-mice ( Fig. 3c) . However, we did not detect differences in kidney weight/body weight ratio ( Fig.   3b,d ), cystic index (Fig. 3b,e) , or BUN (Fig. 3f) (Fig. 4) .
Discussion
Tolvaptan is the first FDA approved drug that has been shown to slow cyst growth and preserve renal function in patients with ADPKD. However, the relative limited benefit and significant side effects of tolvaptan treatment highlights the critical need to utilize unbiased approaches to broadly screen ADPKD kidneys for new therapeutic targets to slow cyst growth and/or interstitial fibrosis in patients with ADPKD. We utilized a powerful kinome wide method to identify in an unbiased manner kinases more active in PKD kidneys when compared with WT control kidneys with the goal that identifying a more complete list of kinases relevant to cyst growth in vivo would offer the potential to find better and safer therapeutic drug targets to treat patients with ADPKD. In addition, a more complete picture of kinases activated in PKD and the signaling pathways they regulate should provide additional insights into the signaling hubs and networks that are aberrantly activated in PKD kidneys and provide clearer links between upstream and downstream signaling pathways.
DDR1 was one of many kinases identified in our screen that was more active in PKD kidneys and was localized to cyst lining epithelia. The relevance of DDR1 to cancer progression, its potential role in the pathogenesis of a variety of other kidney disease, together with the possibility that DDR1 would provide new insight into how extracellular matrix impacts cyst growth suggested to us that DDR1 was an exciting and promising candidate to study. However, the inability of genetically deleting DDR1 to slow cyst growth and preserve renal function in both an "early rapid" and "late slow" mouse model of PKD conclusively demonstrates that DDR1 does not play a role in PKD pathogenesis and thus is not a viable drug target.
In spite of our negative results, we think publication of our findings will be of interest and value to the PKD and nephrology community. First, these studies will prevent other researchers from potentially spending money and time assessing the relevance of DDR1 to PKD pathogenesis. Second, our studies provide an important proof of principle whereby new technologies can be used to rapidly screen for potential new drug targets, which then can be rapidly assessed in vivo for their relevance to disease using CRISPR/Cas9, an approach we are currently undertaking in the lab with success. Third, our findings reinforce the importance of a dasatinib-sensitive kinase(s) in PKD pathogenesis. Identifying the dasatinib specific kinase(s) that contributes to pathogenesis coupled with a drug that more specifically targets this kinase(s), could potentially lead to a safe and efficacious drug to treat patients. 
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